Lightbridge (LTBR) 10-Q 19 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 17, 2014
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Trading Symbol	'ltbr	'
Entity Registrant Name	'LIGHTBRIDGE Corp	'
Entity Central Index Key	'0001084554	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	18,082,874
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Well Known Seasoned Issuer	'No	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current Assets	'	'
Cash and cash equivalents	$440,837	$3,672,877
Marketable securities	16,287	15,731
Restricted cash	555,842	555,008
Accounts receivable - project revenue and reimbursable project costs	138,026	425,916
Prepaid expenses & other current assets	300,398	288,939
Total Current Assets	1,451,390	4,958,471
Property Plant and Equipment -net	0	0
Other Assets	'	'
Patent costs - net	801,447	699,168
Total Assets	2,252,837	5,657,639
Current Liabilities	'	'
Accounts payable and accrued liabilities	389,404	476,628
Total Current Liabilities	389,404	476,628
Stockholders' Equity	'	'
Preferred stock, $0.001 par value, 50,000,000 authorized shares, no shares issued and outstanding	0	0
Common stock, $0.001 par value, 500,000,000 authorized, 15,204,358 shares outstanding and 15,057,243 shares outstanding at September 30, 2014 and December 31, 2013, respectively	15,204	15,057
Additional paid in capital - stock and stock equivalents	76,776,381	76,243,764
Deficit	-74,928,152	-71,077,810
Total Stockholders' Equity	1,863,433	5,181,011
Total Liabilities and Stockholders' Equity	$2,252,837	$5,657,639

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred Stock, Par Value Per Share	$0.00	$0.00
Preferred Stock, Shares Authorized	50,000,000	50,000,000
Preferred Stock, Shares Issued	'	'
Preferred Stock, Shares Outstanding	'	'
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	15,204,358	15,057,243
Common Stock, Shares, Outstanding	15,204,358	15,057,243

Condensed_Unaudited_Consolidat

Condensed Unaudited Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue:	'	'	'	'
Consulting Revenue	$275,158	$169,156	$878,396	$1,343,964
Cost of Consulting Services Provided	136,061	128,780	492,047	778,821
Gross Margin	139,097	40,376	386,349	565,143
Operating Expenses	'	'	'	'
General and administrative	783,570	804,907	3,064,309	2,358,769
Research and development expenses	116,146	557,729	1,172,680	1,816,284
Total Operating Expenses	899,716	1,362,636	4,236,989	4,175,053
Operating Loss	-760,619	-1,322,260	-3,850,640	-3,609,910
Other Income and (Expenses)	'	'	'	'
Investment income	44	2,476	1,391	-9,277
Other income (expenses)	-737	505	-1,093	-2,859
Total Other Income and (Expenses)	-693	2,981	298	-12,136
Net loss before income taxes	-761,312	-1,319,279	-3,850,342	-3,622,046
Income taxes	0	0	0	0
Net loss	($761,312)	($1,319,279)	($3,850,342)	($3,622,046)
Net Loss Per Common Share, Basic and Diluted	($0.05)	($0.11)	($0.26)	($0.29)
Weighted Average Number of Shares Outstanding	15,111,383	12,556,400	15,079,222	12,550,850

Condensed_Unaudited_Consolidat1

Condensed Unaudited Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Operating Activities:	'	'
Net Loss	($3,850,342)	($3,622,046)
Adjustments to reconcile net loss from operations to net cash used in operating activities:	'	'
Stock-based compensation	227,274	273,558
Depreciation and amortization	0	15,202
Unrealized and realized (gains) loss on marketable securities	-556	49,116
Changes in non-cash operating working capital items:	'	'
Accounts receivable - fees and reimbursable project costs	287,890	-26,986
Prepaid expenses and other assets	-11,459	125,831
Accounts payable, accrued liabilities and other current liabilities	-87,224	-102,884
Net Cash Used In Operating Activities	-3,434,417	-3,288,209
Investing Activities:	'	'
Proceeds from the sale of marketable securities	0	1,572,242
Purchase of Marketable securities	0	-38,133
Patent costs	-102,279	-71,809
Net Cash Provided by (Used In) Investing Activities	-102,279	1,462,300
Financing Activities:	'	'
Net proceeds from the issuance of common stock	305,490	0
Stock offering costs	0	-8,000
Redemption of common stock into treasury stock	0	0
Restricted cash	-834	-1,049
Net Cash Provided by (Used In) Financing Activities	304,656	-9,049
Net Decrease In Cash and Cash Equivalents	-3,232,040	-1,834,958
Cash and Cash Equivalents, Beginning of Period	3,672,877	2,197,555
Cash and Cash Equivalents, End of Period	440,837	362,597
Cash paid during the year:	'	'
Interest paid	0	0
Income taxes paid	$0	$0

Basis_of_Presentation_Summary_

Basis of Presentation, Summary of Significant Accounting Policies and Nature of Operations	9 Months Ended
	Sep. 30, 2014
Basis of Presentation, Summary of Significant Accounting Policies and Nature of Operations [Text Block]	'
	Note 1. Basis of Presentation, Summary of Significant Accounting Policies and Nature of Operations
	Basis of presentation
	The accompanying unaudited condensed consolidated financial statements of Lightbridge Corporation and its subsidiaries have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or the SEC, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive consolidated financial statements and should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2013, included in our Annual Report on Form 10-K for the year ended December 31, 2013.
	In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three month period have been made. Results for the interim period presented are not necessarily indicative of the results that might be expected for the entire fiscal year. When used in these notes, the terms "Company,” "we,” "us" or "our" mean Lightbridge Corporation and all entities included in our consolidated financial statements.
	We were formed on October 6, 2006, when Thorium Power, Ltd. merged with Thorium Power, Inc., (“TPI”), which had been formed in the State of Delaware on January 8, 1992. On September 29, 2009, we changed our name from Thorium Power, Ltd. to Lightbridge Corporation (“Lightbridge” or the “Company”). We are engaged in two operating business segments: our Technology Business Segment and our Consulting Business Segment (see Note 9-Business Segment Results).
	Technology Business Segment
	Our primary business segment, based on future revenue potential, is to develop innovative, proprietary nuclear fuel designs which we expect will significantly enhance the nuclear power industry’s economics and increase power output by: (1) providing an increase in power output of up to 10% while simultaneously extending the operating cycle length from 18 to 24 months in existing pressurized water reactors (which are currently limited to an 18 -month operating cycle); alternatively, the power can be increased up to 17% while retaining an 18 -month operating cycle; (2) enabling increased reactor power output (up to 30% increase) without changing the core size in new build PWRs; and (3) reducing the volume of used fuel per kilowatt-hour as well as enhancing proliferation resistance of spent fuel. There are significant technology synergies among our primary fuel products due to utilization of the proprietary metallic fuel rod technology that is at the core of each of them. Once completed, a full-scale demonstration and qualification of the metallic fuel rod technology will simultaneously advance all of our product families currently under development. Due to the significantly lower temperature during operation, our metallic nuclear fuel rods are expected to have improved safety margins during off-normal events.
	U.S. Nuclear Regulatory Commission processes require engineering analysis of a large break loss-of-coolant accident (LOCA). The scenario assumes failure of a large water pipe in the reactor coolant system. Under LOCA conditions, the fuel and cladding temperatures rise due to reduced cooling capacity. Preliminary analytical modeling shows that under a LOCA scenario, unlike conventional uranium dioxide fuel, the cladding of the Lightbridge-designed metallic fuel rods would stay at least 200 degrees below the 850-900 degrees Celsius temperature at which steam begins to react with the zirconium cladding generating hydrogen gas. Buildup of hydrogen gas in a nuclear power plant can lead to a detonation. Lightbridge fuel is designed to prevent hydrogen gas generation in LOCA situations.
	We are currently focusing our development efforts primarily on the metallic fuel with a power uprate of up to 10% and a 24 -month operating cycle in existing Westinghouse-type four-loop pressurized water reactors. Those reactors represent the largest segment of our global target market. Our metallic fuel could also be adapted for use in other types of water-cooled commercial power reactors, such as boiling water reactors, CANDU heavy water reactors, as well as water-cooled small modular reactors.
	On October 20, 2014, we announced the signing of an initial cooperation agreement with Canadian Nuclear Laboratories (CNL), formerly known as Atomic Energy of Canada Limited-Chalk River Laboratories, for fabrication and test reactor irradiation of Lightbridge's patented next generation metallic nuclear fuel samples. The work will take place at CNL's facilities at Chalk River, Ontario, Canada.
	Consulting Business Segment
	Our business model expanded with the establishment of a consulting business segment in 2007, through which we provide consulting and strategic advisory services to companies and governments planning to create or expand electricity generation capabilities using nuclear power plants. On August 1, 2008, we signed separate consulting services agreements with two government entities: Emirates Nuclear Energy Corporation (“ENEC”) formed by Abu Dhabi, one of the member Emirates of the United Arab Emirates (“UAE”), and the Federal Authority for Nuclear Regulation (“FANR”) formed by the government of the UAE. Under these two original agreements, we have provided consulting and strategic advisory services over a contract term of five years starting from June 23, 2008. The ENEC contract has been extended through 2015. The FANR contract has been extended to December 31, 2014. However, we have been notified by FANR that they plan to extend the contract to December 31, 2016. The amended agreement is dependent upon obtaining final signatures. These contracts can each continue to be extended upon agreement by both parties.
	On October 7, 2013, we were selected as technical advisor to provide independent re-verification of equipment and material procurement processes related to construction and maintenance of nuclear power plants operated by Korea Hydro and Nuclear Power Company (KHNP). As a subcontractor to London-based Lloyd's Register Group Limited, we will focus on the environmental and seismic qualification and commercial grade dedication aspects of a two-year Lloyd's Register/KHNP contract.
	On August 11, 2014, we were selected to provide quality assurance, safety and construction inspection services in support of the in-house inspection team of FANR. As a team with Lloyd’s Register, this work is in addition to our ongoing support of FANR’s activities.
	On August 14, 2014 we signed a Memorandum of Understanding with the Vietnam Agency for Radiation and Nuclear Safety (VARANS) to provide regulatory, legal, and administrative support to Vietnam’s civil nuclear program.
	On October 17, 2014 we signed with the Vietnam Atomic Energy Institute (VINATOM) a comprehensive cooperation agreement for consulting services related to the construction and safe operation of Vietnam's Atomic Energy Research Center, including a nuclear research reactor. Our collaboration with VINATOM involves 24 specific activities, including design review and selection of nuclear research reactors, site selection, and nuclear security protocols.
	On October 17, 2014 we signed with Vietnam's leading energy engineering consultant, Power Engineering Consulting Joint Stock Company 1 (PECC1), a teaming agreement for consulting services related to construction and safe operation of a nuclear research reactor, which is planned as part of the country's Center for Nuclear Energy Science and Technology (CNEST). Work under the five-year, Lightbridge/VINATOM agreement will support CNEST, Vietnam's nuclear science and technology center, a planned $500 million facility. The VINATOM agreement also stipulates support for nuclear quality assurance; research-reactor fuel selection; control-room operations; safeguards, control and accounting of nuclear material; and related training programs.
	Accounting Policies and Pronouncements
	Basis of Consolidation
	These financial statements include the accounts of Lightbridge, a Nevada corporation, and our wholly-owned subsidiaries, Thorium Power Inc., a Delaware corporation, Lightbridge International Holding LLC, a Delaware limited liability company and our foreign branch offices.
	All significant intercompany transactions and balances have been eliminated in consolidation. We registered a branch office in the United Kingdom in 2008 called Lightbridge Advisors Limited and we also established a branch office in Moscow, Russia, in July 2009, both of which are wholly owned by Lightbridge International Holding LLC. Translation gains and losses for the three months and nine months ended September 30, 2014 and September 30, 2013, were not significant.
	Use of Estimates and Assumptions
	The preparation of financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Significant Estimates
	These accompanying consolidated financial statements include some amounts that are based on management’s best estimates and judgments. The most significant estimates relate to valuation of stock grants and stock options, the valuation allowance on deferred tax assets and various contingent liabilities. It is reasonably possible that these above-mentioned estimates and others may be adjusted as more current information becomes available, and any adjustment could be significant in future reporting periods. It is also reasonably possible that the actual grant date value of the stock options vested might have been materially different than the estimated value.
	Certain Risks, Uncertainties and Concentrations
	We are an early stage company and will likely need additional funding by way of strategic alliances, further offerings of equity securities, an offering of debt securities, or a financing through a bank in order to support the remaining research and development activities required to further enhance and complete the development of our fuel products to a commercial stage. Currently, we are working on consulting revenue opportunities with the overall goal of increasing our profitability and cash flow.
	We participate in a government-regulated industry. Our operating results are affected by a wide variety of factors including decreases in the use or public favor of nuclear power, the ability of our technology to safeguard the production of nuclear power and our ability to safeguard our patents and intellectual property from competitors. Due to these factors, we may experience substantial period-to-period fluctuations in our future operating results. Potentially, a loss of a key officer, key management, and other personnel could impair our ability to successfully execute our business strategy, particularly when these individuals have acquired specialized knowledge and skills with respect to nuclear power and our operations.
	Our future operations and earnings currently depend on the results of the Company’s operations outside the United States. There can be no assurance that the Company will be able to successfully continue to conduct such operations, and a failure to do so would have a material adverse effect on the Company’s research and development activities, financial position, results of operations, and cash flows. Also, the success of the Company’s operations will be subject to other numerous contingencies, some of which are beyond management’s control. These contingencies include general and regional economic conditions, competition, changes in regulations, changes in accounting and taxation standards, inability to achieve overall long-term goals, future impairment charges and global or regional catastrophic events. Because the Company is dependent on its international operations for almost all its revenue, the Company may be subject to various additional political, economic, and other uncertainties.
	Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash equivalents and accounts receivable. Cash equivalents consist of a checking account held with one major financial institution with a high credit standing.
	Accounts receivable are typically unsecured and are primarily derived from revenues earned from customers located in the Middle East. We perform ongoing evaluations to determine customer credit and we limit the amount of credit we extend, but generally we do not require collateral from our customers. We maintain reserves for estimated credit losses; however, no reserve has been set up for 2014 and 2013, as we have not incurred any credit losses from our customers to date. Approximately 67% and 99% and 74% and 99% of our consulting revenues were from our Middle East contracts for the three months and nine months ended September 30, 2014 and 2013, respectively.
	Revenue Recognition
	Consulting Business Segment
	At present, we derive all of our revenue from our consulting and strategic advisory services business segment, by performing consulting services for governments outside the United States planning to create or expand electricity generation capabilities using nuclear power plants. Our fee structure for each client engagement is dependent on a number of variables, including the size of the client, the complexity of the project, the level of the opportunity for us to improve the client’s electrical generation capabilities using nuclear power plants, and other factors. The accounting policy we use to recognize revenue depends on the terms and conditions of the specific contract.
	Revenues from government-owned entities in the UAE are billed and recognized on a time and expense basis.
	Certain customer arrangements require evaluation of the criteria outlined in the accounting standards for reporting revenue “ Gross as a Principal Versus Net as an Agent ” in determining whether it is appropriate to record the gross amount of revenue and related costs, or the net amount earned as agent fees. Generally, when we are primarily obligated in a transaction, revenue is recorded on a gross basis. Other factors that we consider in determining whether to recognize revenue on a gross versus net basis include our assumption of credit risk, latitude in establishing prices, our determination of service specifications and our involvement in the provision of services. We have determined, based on the credit risk that we bear for collecting consulting fees, travel costs and other reimbursable costs from our customers, that in 2014 and 2013 we acted as a principal, and therefore we are recognizing as revenue all travel costs and other reimbursable costs billed to our customers.
	Cost of consulting services includes labor, travel expenses and other related consulting costs. All costs directly related to producing work under certain consulting agreements where revenue is recognized upon acceptance of certain contractual milestones by our customer, are first capitalized as deferred project costs. Deferred project costs are then recognized or amortized to an expense captioned “cost of consulting services provided” on the accompanying consolidated statement of operations, when the revenue is recognized upon the delivery and acceptance of the defined contractual milestones or deliverables.
	Technology Business Segment
	Once our nuclear fuel designs have advanced to a commercially usable stage by a fuel fabricator and/or nuclear plant owner/operator, we will seek to license our technology to them or to major government contractors working for the applicable government. We expect that our revenue from these license fees will be recognized on a straight-line basis over the expected period of the related license term.
	Stock-Based Compensation
	The stock-based compensation expense incurred by Lightbridge for employees and directors in connection with its stock option plan is based on the employee model of ASC 718, and the fair market value of the options is measured at the grant date. Under ASC 718 employee is defined as, “An individual over whom the grantor of a share-based compensation award exercises or has the right to exercise sufficient control to establish an employer-employee relationship based on common law as illustrated in case law and currently under U.S. Tax Regulations.” Our advisory board members and consultants do not meet the employer-employee relationship as defined by the IRS and therefore are accounted for under ASC 505-50.
	ASC 505-50-30-11 (previously EITF 96-18) further provides that an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date:
		i.	The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and
		ii.	The date at which the counterparty’s performance is complete.
	We have elected to use the Black-Scholes pricing model to determine the fair value of stock options on the measurement date of the grant. Restricted stock units are measured based on the fair market values of the underlying stock on the measurement date of the grant. Shares that are issued to officers on the exercise dates of their stock options may be issued net of the statutory withholding requirements to be paid by us on behalf of our employees. As a result, the actual number of shares issued will be fewer than the actual number of shares exercised under the stock option. We recognize stock-based compensation using the straight-line method.
	For the three months ended September 30, 2014 and 2013, we recognized stock-based compensation of approximately $0.1 million and $0.1 million. For the nine months ended September 30, 2014 and 2013, we recognized stock-based compensation of approximately $0.2 million and $0.3 million, respectively. Related income tax benefits were not recognized, as we incurred a tax loss for both years.
	Fair Value of Financial Instruments
	The carrying amounts of our financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value because of their generally short maturities. We carry marketable securities at fair value.
	Cash and Cash Equivalents, Restricted Cash and Marketable Securities
	We invest our excess cash in money market mutual funds, and mutual bond funds. We classify all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. We hold cash balances in excess of the federally insured limits of $250,000 with one prominent financial institution. We deem this credit risk not to be significant as our cash is held by a major prominent financial institution. Total cash and cash equivalents held in checking accounts and a money market core cash account, as reported on the accompanying consolidated balance sheets, totaled approximately $0.4 million and $3.7 million at September 30, 2014 and December 31, 2013, respectively.
	Restricted cash represents cash being held by the same prominent financial institution that is being used as collateral for our corporate credit cards and future letters of credit that we may issue to some of our foreign customers. The total balance of our restricted cash at September 30, 2014 and December 31, 2013, was approximately $0.6 million.
	We determine the appropriate classification of our investments in marketable securities at the time of purchase and reevaluate such designation at each balance sheet date. We have classified and accounted for our marketable securities as available-for-sale, however, we carry these securities at fair value (see below election made to value these financial instruments at fair market value). The fair value of substantially all securities is determined by quoted market prices.
	All marketable securities are classified as available-for-sale securities and are reported at their fair value (level 1). A level 1 measurement under the FASB pronouncements is the first tier of a three tier hierarchy for fair value measurements used in valuation methodologies. This valuation level allows for fair value measurements where the inputs are the quoted prices for the assets in the active markets. All of our marketable securities have quoted market prices and these quoted prices are used to determine the fair value of our marketable securities.
	The total quoted fair value of our marketable securities at September 30, 2014 and December 31, 2013, was approximately $16,000. This amount was held in Vanguard High Yield Corp Investor Fund (Symbol -VWEHX). The cost basis of this above investment was approximately $15,000.
	Investment Income (loss) is earned on marketable securities and consists of unrealized gains (losses), realized capital gains or losses, interest and dividends received, as reported to us from the financial institutions in which they were reinvested, and totaled approximately $0 and $2,000 for each of the three month periods ended September 30, 2014 and 2013, respectively, and $1,000 and $(9,000) for each of the nine months ended September 30, 2014 and 2013, respectively. We elected the fair value option permitted under FASB ASC 825 to report the unrealized gains and losses from our marketable securities in our accompanying consolidated statement of operations instead of other comprehensive income and loss. Management believes the fair value option provides a better indication of the Company’s performance.
	Trade Accounts Receivable
	We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers which are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credits issued.
	There was no provision for doubtful accounts recorded at September 30, 2014 and December 31, 2013, as we have not experienced any bad debt write-offs from any of our customers. Substantially all accounts receivable at September 30, 2014 and December 31, 2013, are from the FANR and ENEC contracts (see Note 3-Accounts Receivable – Project Revenue and Reimbursable Project Costs).
	Income Taxes
	Income taxes are accounted for under the asset and liability method in accordance with United States generally accepted accounting principles. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized. We did not provide any current or deferred income tax provision or benefit for any periods presented to date because we have continued to experience a net operating loss since inception and therefore provide a 100% valuation allowance against all of our deferred tax assets (see Note 8–Income Taxes).
	The Company adopted the ASC standards relating to “ Accounting for Uncertainty in Income Taxes .” This pronouncement provides guidance for recognizing and measuring uncertain tax positions, as defined in the FASB accounting pronouncement “ Accounting for Income Taxes .” This pronouncement prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. This pronouncement also provides accounting guidance on derecognizing, classification and disclosure of these uncertain tax positions. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company has not recognized any interest and penalties in 2014 or 2013.
	Foreign Currency
	The functional currency of our international branches is the local currency. We translate the financial statements of these branches to U.S. dollars using period-end rates of exchange for assets and liabilities, and average rates of exchange for revenues, costs, and expenses. The translation gains/losses for our branch office in Russia were not significant for the three and nine months ended September 30, 2014 and 2013.
Patents and Legal Costs
Patents are stated on the accompanying consolidated balance sheets at cost less accumulated amortization. The costs of the patents, once placed in service, will be amortized on a straight-line basis over their estimated useful lives or the remaining legal lives of the patents, whichever is shorter. The amortization periods for our patents can range between 17 and 20 years if placed into service at the beginning of their legal lives. Our patents have not been placed in service for the three months and nine months ended September 30, 2014 and 2013.
Legal costs are expensed as incurred except for legal costs to file for patent protection, which are capitalized and reported as patents on the accompanying consolidated balance sheets.
Impairment of long-lived assets
Long-lived assets of the Company are reviewed for impairment whenever events or circumstances indicate that the carrying amount of assets may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company did not consider it necessary to record any impairment charges for the three months and nine months ended September 30, 2014 and 2013.
Research, Development and Related Expenses
These costs from our Technology business segment are charged to operations in the period incurred and are shown on a separate line on the accompanying Consolidated Statements of Operations. Research and development and related expenses totaled approximately $0.1 million and $0.6 million for the three months ended September 30, 2014 and 2013, respectively. Research and development and related expenses totaled approximately $1.2 million and $1.8 million for the nine months ended September 30, 2014 and 2013, respectively.
Segment Reporting
We use the “management approach” in determining reportable operating segments. The management approach considers the internal organization and reporting used by our chief decision makers for making operating decisions and assessing performance, as the source for determining our reportable segments. We have determined that we have two operating segments as defined by the FASB accounting pronouncement, “ Disclosures about Segments of an Enterprise and Related Information .” As discussed above, our two reporting business segments are our technology business and our consulting services business (See Note 9 - Business Segment Results).
Commitments and Contingencies
The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to account for and report contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment.
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.
Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. The Company’s legal costs associated with contingent liabilities are recorded to expense as incurred.
Recent Accounting Pronouncements
In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016, (early adoption is not permitted). The guidance permits the use of either a retrospective or cumulative effect transition method.
The Company does not expect the adoption of any recent accounting pronouncements to have a material impact on its financial statements.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2014
Net Loss Per Share [Text Block]	'
	Note 2. Net Loss Per Share
	Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period except that it does not include unvested common shares subject to repurchase or cancellation. Diluted net income per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options, warrants, restricted shares, and unvested common shares subject to repurchase or cancellation. The dilutive effect of outstanding stock options, restricted shares, restricted stock units, and warrants is not reflected in diluted earnings per share because we incurred net losses for the three months and nine months ended September 30, 2014 and 2013, and the effect of including these potential common shares in the diluted earnings per share calculations would be anti-dilutive and are therefore not included in the calculations.

Accounts_Receivable_Project_Re

Accounts Receivable -Project Revenue and Reimbursable Project Costs	9 Months Ended
	Sep. 30, 2014
Accounts Receivable -Project Revenue and Reimbursable Project Costs [Text Block]	'
	Note 3. Accounts Receivable – Project Revenue and Reimbursable Project Costs
	FANR Projects
	The total accounts receivable from the ENEC and FANR contracts was approximately $0.1 million and $0.4 million at September 30, 2014 and December 31, 2013. These amounts due from FANR represent approximately 37% of the accounts receivable reported at September 30, 2014, and substantially all of the accounts receivable at December 31, 2013. Approximately 74% and 100% of the total revenues reported for the nine months ended September 30, 2014 and 2013, respectively, were from the ENEC and FANR contracts. One other contract, outside of the Middle East, constituted 20% of the total revenues reported for the nine months ended September 30, 2014.
	Total unbilled accounts receivable of approximately $0.1 million was included in the accompanying consolidated balance sheets and reported in accounts receivable at September 30, 2014 and December 31, 2013, and is for work that was billed to our clients in October 2014 and January 2014, respectively. Foreign currency transaction exchange losses and translation gains and losses for the three months and nine months ended September 30, 2014 and 2013, were not significant.
	Travel costs and other reimbursable costs under these contracts are reported in the accompanying statement of operations as both revenue and cost of consulting services provided, and totaled approximately $0.1 million for the three month and nine month periods ended September 30, 2014 and 2013. The total travel and other reimbursable expenses that have not been reimbursed to us and are included in total accounts receivable reported above from our consulting contracts were not significant at September 30, 2014 and December 31, 2013.
	Under our agreements with ENEC and FANR, revenue will be recognized on a time and expense basis. We periodically discuss our consulting work with ENEC and FANR, who will review the work we perform, and our reimbursable travel expenses, and accept our monthly invoicing for services and reimbursable expenses. We expect the variation of revenue we earn from these contracts to continue.

Accounts_Payable_and_Accrued_L

Accounts Payable and Accrued Liabilities	9 Months Ended
	Sep. 30, 2014
Accounts Payable and Accrued Liabilities [Text Block]	'
	Note 4. Accounts Payable and Accrued Liabilities
	Accounts payable and accrued expenses (in millions) consisted of the following:
			30-Sep-14		31-Dec-13
	Trade payables	$	0.1	$	0.1
	Accrued expenses and other		0.2		0.1
	Accrued payroll liabilities		0.1		0.3
	Total	$	0.4	$	0.5

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Taxes [Text Block]	'
	Note 5. Income Taxes
	Our tax provision is determined using an estimate of our annual effective tax rate adjusted for discrete items, if any, that are taken into account in the relevant period. The 2014 and 2013 annual effective tax rate is estimated to be a combined 40% for the U.S. federal and state statutory tax rate. We review tax uncertainties in light of changing facts and circumstances and adjust them accordingly. As of September 30, 2014 and December 31, 2013, there were no tax contingencies recorded.
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities recognized for financial reporting, and the amounts recognized for income tax purposes. The significant components of deferred tax assets (at a 40% effective tax rate) as of September 30, 2014 and December 31, 2013, respectively, are as follows:
	Deferred Tax Assets (in millions)
			Total			Total			Deferred Tax Asset
			Sept. 30,			Dec. 31,			Sept. 30,			Dec. 31,
			2014			2013			2014			2013
	Capitalized start-up costs	$	4.2		$	4.6		$	1.7		$	1.8
	Stock-based compensation		17.8			17.6			7.1			7
	Net operating loss carry-forward		44.2			40.5			17.7			16.2
	Less: valuation allowance		(66.2	)		(62.7	)		(26.5	)		(25.0	)
		$	-		$	-		$	-		$	-
	We have a net operating loss carry-forward for federal and state tax purposes of approximately $44 million at September 30, 2014, that is potentially available to offset future taxable income, which will begin to expire in the year 2021. For financial reporting purposes, no deferred tax asset was recognized because at September 30, 2014 and December 31, 2013, management estimates that it is more likely than not that substantially all of the net operating losses will expire unused. As a result, the amount of the deferred tax assets considered realizable was reduced 100% by a valuation allowance. The change in the valuation allowance was approximately $1.5 million and $1.5 million for the nine months ended September 30, 2014 and 2013, respectively. Many of the Company’s operating expenses in its 2007 and 2006 tax years were classified under the Internal Revenue Code as capitalized “Startup Costs,” which did not begin to be deductible for tax purposes until 2008. The Company files a consolidated tax return with its subsidiaries. The Company is no longer subject to U.S. federal, state, or non-U.S. income tax examinations by tax authorities for tax years before 2010, except that earlier years can be examined for the sole purpose of challenging the net operating loss carry-forwards arising in those years.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies [Text Block]	'
	Note 6. Commitments and Contingencies
	Employment Agreements
	We have employment agreements with our executive officers and some consultants, the terms of which expire at various times. Such agreements provide for minimum compensation levels, as well as incentive bonuses that are payable if specified management goals are attained. Under each of the agreements, in the event the officer's employment is terminated (other than voluntarily by the officer or by us for cause, or upon the death of the officer), if all provisions of the employment agreements are met, we are committed to pay certain benefits, including specified monthly severance.
	Operating Leases
	On October 16, 2013, we entered into a 1 year sub-lease agreement with our current landlord for our current office space starting January 1, 2014. The monthly rent payment is approximately $32,000 plus additional charges.
	On September 3, 2014 we signed a new lease agreement for the existing property that has a lease term of 38 months, starting January 1, 2015. The monthly rent payment is approximately $32,000 plus additional charges.
	We pay rent for our Moscow office of approximately $12,000 per month, on a month-to-month basis.
	Total rent expense was approximately $0.1 million and $0.2 million for each of the three months periods ended September 30, 2014 and 2013, respectively and approximately $0.4 million and $0.5 million for each of the nine months periods ended September 30, 2014 and 2013, respectively.

Research_and_Development_Costs

Research and Development Costs	9 Months Ended
	Sep. 30, 2014
Research and Development Costs [Text Block]	'
	Note 7. Research and Development Costs
	Research and Development Costs
	Research and development costs, included in the accompanying consolidated statement of operations amounted to approximately $0.1 million and $0.6 million for the three month periods ended September 30, 2014 and 2013, and $1.2 million and $1.8 million for the nine months ended September 30, 2014 and 2013, respectively.
	On October 20, 2014, we announced the signing of an initial cooperation agreement with Canadian Nuclear Laboratories (CNL), formerly known as Atomic Energy of Canada Limited-Chalk River Laboratories, for fabrication and test reactor irradiation of Lightbridge's patented next generation metallic nuclear fuel samples. The work will take place at CNL's facilities at Chalk River, Ontario, Canada. The joint work will proceed in three phases that will address:
	•	Quality management planning to ensure compliance with the U.S. Nuclear Regulatory Commission requirements for fabrication and loop irradiation testing of fuel samples (Phase I);
	•	Development of a fabrication plan and a preliminary experiment design for loop irradiation testing (Phase II); and
	•	Fabrication and irradiation of Lightbridge-designed metallic fuel samples (Phase III).
	The Initial Cooperation Agreement enables the Phase I work. Over the next several months, we intend to complete negotiations relating to two other enabling agreements:
	•	Nuclear Engineering Services Agreement that will address Phase II; and
	•	Umbrella Services Agreement that will provide a comprehensive legal framework for multi-year cooperation between the parties to enable the final phase of work to proceed.
	The Initial Cooperation Agreement is non-exclusive and does not prevent either party from working with other fuel fabrication or fuel development partners.
	We have consulting agreements with several consultants working on various projects for us, which total approximately $10,000 per month.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity [Text Block]	'
	Note 8. Stockholders’ Equity
	At September 30, 2014 and December 31, 2013, there were 500,000,000 shares of authorized common stock. Total common stock outstanding at September 30, 2014 and December 31, 2013, was 15,204,358 shares and 15,057,243 shares, respectively. At September 30, 2014, there were 2,152,174 stock warrants and 2,143,686 stock options outstanding, all totaling 19,500,218 of total stock and stock equivalents outstanding at September 30, 2014.
	Registered Direct Offerings and Outstanding Warrants
	October 21, 2013 Offering
	On October 21, 2013, we completed an offering with certain institutional investors for the sale of 2,500,000 shares of our common stock and warrants to purchase a total of 1,250,000 shares of our common stock for aggregate gross proceeds, before deducting fees to the Placement Agent and other estimated offering expenses payable by us, of approximately $4.4 million (the “Oct. 2013 Offering”). The common stock and warrants were sold in fixed combinations, with each combination consisting of one share of common stock and a warrant to purchase 0.5 shares of common stock. The purchase price was $1.75 per fixed combination. The warrants become exercisable nine months and one day following the closing date (October 21, 2013, i.e., exercisable beginning April 22, 2014) of the offering and will remain exercisable for 7.5 years from the date of issuance at an exercise price of $2.30 per share. The exercise price of the warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. The exercisability of some of the warrants may be limited if, upon exercise, the holder or any of its affiliates would beneficially own more than 4.99% of our common stock. This limit may be increased to up to 9.99% upon no fewer than 60 days' notice.
	We received net proceeds of approximately $4.0 million after payment of certain fees and expenses related to the Oct. 2013 Offering. The allocation of the proceeds from the offering, based on the relative fair value of the common stock and the warrants, resulted in the allocation of approximately $2.8 million of the net proceeds to the common stock sold and approximately $1.2 million of the net proceeds to the warrants, which was recorded to additional paid-in capital-stock and stock equivalents.
	The value of the warrants issued was calculated by using the Black Scholes Valuation Model using the following assumptions: volatility 104%; risk-free interest rate of 2.01%; dividend yield of 0%, and expected term of 7.5 years. The volatility of the Company’s common stock was estimated by management based on the historical volatility of the trading history of the Company’s common stock. The risk-free interest rate was based on the Treasury Constant Maturity Rates published by the U.S. Federal Reserve for periods applicable to the expected life of the warrants. The expected dividend yield was based on the Company’s current and expected dividend policy and the expected term is equal to the contractual life of the warrants.
	July 22, 2010 Offering - Warrants Outstanding
	On July 22, 2010, we completed an offering (the “July 2010 Offering”) with certain institutional investors for the sale of 2,069,992 shares of our common stock and warrants to purchase a total of 1,034,996 shares of our common stock for aggregate gross proceeds, before deducting fees to the Placement Agent and other estimated offering expenses payable by us, of approximately $13.7 million. The common stock and warrants were sold in fixed combinations, with each combination consisting of one share of common stock and a warrant to purchase 0.5 shares of common stock. The purchase price was $6.60 per fixed combination. The warrants became exercisable nine months and one day following the closing date (July 28, 2010, i.e., exercisable beginning January 29, 2011) of the July 2010 Offering and will remain exercisable for seven years from the date of issuance at an exercise price of $9.00 per share. The exercise price of the warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. The exercisability of some of the warrants may be limited if, upon exercise, the holder or any of its affiliates would beneficially own more than 4.99% of our common stock. This limit may be increased to up to 9.99% upon no fewer than 60 days' notice. All these warrants remain outstanding at September 30, 2014 and December 31, 2013.
	Exercise of Warrants – Q3-14
	On July 4, 2014, we issued 132,822 shares of our common stock upon the exercise of warrants issued in conjunction with the October 21, 2013 stock offering. We received $2.30 for each share issued or approximately $305,000.
	Stock-based Compensation – Stock Options and Restricted Stock
	Stock Plan
	We have a stock-based compensation plan, the 2006 Stock Plan, to reward our officers, directors, employees and consultants for services rendered. On July 17, 2006, we amended this stock plan. We have reserved 2,500,000 shares of common stock for issuance under the stock plan. Other limitations are as follows:
	(i)	No more than an aggregate of 1,250,000 shares can be granted for the purchase of restricted common shares during the term of the stock plan;
	(ii)	The maximum number of shares of common stock with respect to which options may be granted to any one person during any fiscal year may not exceed 266,667 shares; and
	(iii)	The maximum number of restricted shares that may be granted to any one person during any fiscal year may not exceed 166,667 common shares.
	Total stock options outstanding at September 30, 2014 and December 31, 2013, were 2,143,686 and 1,564,257, of which 1,564,257 and 1,530,200 of these options were vested at September 30, 2014 and December 31, 2013, respectively. Stock option expense was approximately $102,000 and $43,000 for the three months ended September 30, 2014 and 2013, respectively. Stock option expense was approximately $207,000 and $189,000 for the nine months ended September 30, 2014 and 2013, respectively.
	On May 5, 2014, we granted 579,429 stock options to our employees, directors and consultants. These stock options vest over three years for employees and consultants, and over one year for our directors. The fair market value of each option was $1.79 on the grant date, based on (1) the strike price of $2.55, the price of our stock at the close of the market on the grant date; (2) the expected life of the grant of 5 years which is equal to the term of the grant, as historically grants have only been exercised just before the term expires; (3) the risk free rate of 1.68% which is based on the treasury yield curve for a 5 year term as published by the U.S. Treasury for the grant date; (4) volatility of 90.44%, as measured based on the expected life of the options, and (5) expected dividends of $0.0, as we have never issued dividends and we have no plans to ever issue dividends. Grants to our consultants were re-measured as of September 30, 2014, and the fair market value of each option was $1.55 on the measurement date. We estimated future pre-vest forfeitures to be 1.5%, based on historical information.
	Stock option transactions to the employees, directors, advisory board members and consultants are summarized as follows for the nine months ended September 30, 2014:
						Weighted		Weighted
			Options			Average		Average
			Outstanding			Exercise		Grant Date
								Fair
						Price		Value
	Beginning of the year		1,564,257		$	11.16	$	10.42
	Granted		579,429			2.55		1.79
	Exercised		-			-		-
	Forfeited		-		$	-	$	-
	Expired		-		$	-	$	-
	End of period		2,143,686		$	8.83	$	8.08
	Options exercisable		1,564,257		$	11.16	$	10.42
	Stock option transactions to the employees, directors, advisory board members and consultants are summarized as follows for the year ended December 31, 2013:
						Weighted		Weighted
			Options			Average		Average
			Outstanding			Exercise		Grant Date
								Fair
						Price		Value
	Beginning of the year		1,639,842		$	11.46	$	10.85
	Granted		-			-		-
	Exercised		-			-		-
	Forfeited		(7,250	)	$	6.04	$	5.51
	Expired		(68,335	)	$	18.94	$	16.9
	End of period		1,564,257		$	11.16	$	10.42
	Options exercisable		1,530,200		$	11.28	$	10.73
	The above tables include options issued and outstanding as of September 30, 2014, as follows:
	i)	A total of 255,202 non-qualified 10 year options have been issued, and are outstanding, to advisory board members at exercise prices ranging from $4.50 to $14.40 per share.
	ii)	A total of 1,677,181 non-qualified 5 - 10 year options have been issued, and are outstanding, to our directors, officers and employees at exercise prices ranging from $2.55 to $23.85 per share. From this total, 820,396 options are held by the Chief Executive Officer who is also a director, with remaining contractual lives ranging from 1.2 years to 6.5 years. All other options issued to directors, officers and employees have a remaining contractual lives ranging from 1.8 years to 6.5 years.
	iii)	A total of 211,303 non-qualified 5 - 10 year options have been issued, and are outstanding, to our consultants at exercise prices ranging from $2.55 to $15.30 per share.
	The following table provides certain information with respect to the above-referenced stock options that are outstanding and exercisable at September 30, 2014:
			Stock Options Outstanding						Stock Options Vested
			Weighted						Weighted
			Average						Average
			Remaining					Weighted	Remaining			Weighted
			Contractual			Number		Average	Contractual	Number		Average
			Life			of		Exercise	Life	of		Exercise
			-Years			Awards		Price	-Years	Awards		Price
	Exercise
	Prices
	$2.55 - $5.00		4.53			762,766	$	3.02	4.31	183,337	$	4.5
	$5.01 - $12.90		4.36			782,584	$	7.45	4.36	782,584	$	7.45
	$13.50 -		1.56			358,336	$	14.17	1.56	358,336	$	14.17
	$19.20 -		1.37			240,000	$	23.85	1.37	240,000	$	23.85
Total		3.62			2,143,686	$	8.83	3.26	1,564,257	$	11.16
The following table provides certain information with respect to the above-referenced stock options that are outstanding and exercisable at December 31, 2013:
		Stock Options Outstanding						Stock Options Vested
		Weighted						Weighted
		Average						Average
		Remaining					Weighted	Remaining			Weighted
		Contractual			Number		Average	Contractual	Number		Average
		Life			of		Exercise	Life	of		Exercise
		-Years			Awards		Price	-Years	Awards		Price
Exercise Prices
$2.55 - $5.00		5.06			183,337	$	4.5	5.06	183,337	$	4.5
$5.01 - $12.90		5.11			782,584	$	7.45	5.03	748,527	$	7.53
$13.50 -		2.3			358,336	$	14.17	2.3	358,336	$	14.17
$19.20 -		2.12			240,000	$	23.85	2.12	240,000	$	23.85
Total		4			1,564,257	$	11.16	3.94	1,530,200	$	11.28
The aggregate intrinsic value of stock options outstanding at September 30, 2014 and December 31, 2013, was $0. Intrinsic value is calculated based on the difference between the exercise price of the underlying awards and the quoted price of our common stock as of the reporting date ($2.30 and $1.45 per share as of the close on September 30, 2014 and December 31, 2013, respectively).
Restricted Stock Award Activity
					Weighted
					Average
					Grant
		Number of			Date Fair
		Units			Value
Total awards outstanding at December 31, 2012		43,032		$	6.49
Units granted		-		$	-
Units Exercised/Released		(28,739	)	$	6.99
Units Cancelled/Forfeited		-		$	-
Total awards outstanding at December 31, 2013		14,293		$	5.47
Units granted		-		$	-
Units Exercised/Released		(14,293	)	$	5.47
Units Cancelled/Forfeited		-		$	-
Total awards outstanding at September 30, 2014		-		$	-
As of September 30, 2014 and December 31, 2013, there was approximately $0 and $19,000 of net unrecognized compensation cost related to unvested restricted stock-based compensation arrangements, respectively. This compensation is recognized on a straight line basis and all of the compensation expected to be expensed in 2014, has been recognized as of September 30, 2014.
We use the historical volatility of our stock price over the number of years that matches the expected life of our stock option grants or we use the historical volatility of our stock price since January 5, 2006, the date we announced that we were becoming a public company, to estimate the future volatility of our stock. At this time we do not believe that there is a better objective method to predict the future volatility of our stock. We estimate the life of our option awards based on the full term of the award. To date we have had very few exercises of our options, and those exercises have occurred just before the expiration date of the awards. Since the strike price of most of our outstanding awards is greater than the price of our stock, generally awards have expired at the end of their term. We estimate the effect of future forfeitures of our grants based on an analysis of historical forfeitures of unvested grants, as we have no better objective basis for that estimate. The expense that we have recognized related to our grants of options and restricted stock includes the estimate for future pre-vest forfeitures. We will adjust the actual expense recognized due to future pre-vest forfeitures as they occur. We have estimated that 1.5% and 0% of our option and restricted stock grants respectively, will be forfeited prior to vesting.
Assumptions used in the Black Scholes option-pricing model for the nine months ended September 30, 2014, were as follows (there were no stock options granted in 2013 or 2012):
		Period
		ended
		9/30/14
Average risk-free interest rate		1.68%
Average expected life- years		5
Expected volatility		90.44%
Expected dividends		0
Stock-based compensation expense includes the expense related to (1) grants of stock options, (2) grants of restricted stock, (3) stock issued as consideration for some of the services provided by our directors and strategic advisory council members, and (4) stock issued in lieu of cash to pay bonuses to our employees and contractors. We record stock-based compensation expenses in the caption with all of our other general and administrative expenses and research and development expenses. Grants of stock options and restricted stock are awarded to our employees, directors, consultants and board members, and we recognize the fair market value of these awards ratably as they are earned. The expense related to payments in stock for services is recognized as the services are provided.
During the three months ended September 30, 2014 and 2013, approximately $0.1 million and $0.1 million respectively, were recorded as total stock-based compensation. During the nine months ended September 30, 2014 and 2013, approximately $0.2 million and $0.3 million, respectively, were recorded as total stock-based compensation. Stock-based compensation expense is recorded under the captions general and administrative expenses and research and development expenses in the accompanying consolidated statements of operations.

Business_Segment_Results

Business Segment Results	9 Months Ended
	Sep. 30, 2014
Business Segment Results [Text Block]	'
	Note 9. Business Segment Results
	We have two principal business segments, which are (1) our technology business and (2) our consulting services business. These business segments were determined based on the nature of the operations and the services offered. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief decision-makers, in deciding how to allocate resources and in assessing performance. Our Chief Executive Officer and Chief Operating Officer/Chief Financial Officer have been identified as the chief operating decision makers. Our chief operating decision makers direct the allocation of resources to operating segments based on the profitability, the cash flows, and the business plans of each respective segment.
	The Company evaluates performance based on several factors, of which achievement of strategic goals toward future profitability and business segment income before taxes are the primary measures. The following tables show the operations of the Company’s reportable business segments for the three months and nine months ended September 30, 2014 and 2013.
	BUSINESS SEGMENT RESULTS – THREE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013
									Corporate and
		Consulting			Technology				Eliminations				Total
		2014	2013		2014		2013		2014		2013		2014		2013
	Revenue	275,158	169,156		-		-		-		-		275,158		169,156
	Segment Profit – Pre Tax	201,954	(103,133	)	(116,145	)	(557,729	)	(847,121	)	(658,417	)	(761,312	)	(1,319,279	)
	Total Assets	138,026	628,789		801,447		672,405		1,313,364		1,383,090		2,252,837		2,684,284
	Property Additions	-	-		-		-		-		-		-		-
	Interest Expense	-	-		-		-		-		-		-		-
	Depreciation	-	-		-		-		-		2,815		-		2,815
	BUSINESS SEGMENT RESULTS – NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013
									Corporate and
		Consulting			Technology				Eliminations				Total
		2014	2013		2014		2013		2014		2013		2014		2013
	Revenue	878,396	1,343,964		-		-		-		-		878,396		1,343,964
	Segment Profit – Pre Tax	284,994	220,875		(1,172,680	)	(1,816,284	)	(2,962,657	)	(2,026,637	)	(3,850,342	)	(3,622,046	)
	Total Assets	138,026	628,789		801,447		672,405		1,313,364		1,383,090		2,252,837		2,684,284
	Property Additions	-	-		-		-		-		-		-		-
	Interest Expense	-	-		-		-		-		-		-		-
	Depreciation	-	-		-		-		-		15,202		-		15,202

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Text Block]	'
	Note 10. Subsequent Events
	The Company has implemented the most recent FASB accounting pronouncement for reporting subsequent events. This standard establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before the consolidated financial statements are issued. The adoption of this accounting pronouncement did not impact our financial position or results of operations. The Company evaluated all events or transactions that occurred after September 30, 2014, up through the date these consolidated financial statements were issued and no subsequent events occurred that required additional disclosure in the accompanying consolidated financial statements other than the November 17, 2014 Offering described in detail below.
	November 17, 2014 Offering
	On November 17, 2014, we completed an offering with one institutional investor for the sale of 2,878,516 shares of our common stock and warrants to purchase a total of 2,734,590 shares of our common stock for aggregate gross proceeds, before deducting fees to the Placement Agent and other estimated offering expenses payable by us, of approximately $5 million (the “Nov. 2014 Offering”). The common stock and warrants were sold in fixed combinations, with each combination consisting of one share of common stock and a warrant to purchase 0.95 shares of common stock. The purchase price was $1.75 per fixed combination. The warrants become exercisable six months and one day following the closing date (November 17, 2014, i.e., exercisable beginning May 18, 2015) of the offering and will remain exercisable for 7.5 years from the date of issuance at an exercise price of $2.31 per share. The exercise price of the warrants is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. The exercisability of some of the warrants may be limited if, upon exercise, the holder or any of its affiliates would beneficially own more than 4.99% of our common stock. This limit may be increased to up to 19.99% upon no fewer than 60 days' notice.
	We received net proceeds of approximately $4.4 million after payment of certain fees and expenses related to the Nov. 2014 Offering. The allocation of the proceeds from the Nov. 2014 offering, based on the relative fair value of the common stock and the warrants, resulted in the allocation of approximately $2.7 million of the net proceeds to the common stock sold and approximately $1.7 million of the net proceeds to the warrants, which was recorded to additional paid-in capital-stock and stock equivalents.
	The value of the warrants issued was calculated by using the Black Scholes Valuation Model using the following assumptions: volatility 66.6%; risk-free interest rate of 2.07%; dividend yield of 0%, and expected term of 7.5 years. The volatility of the Company’s common stock was estimated by management based on the historical volatility of the trading history of the Company’s common stock. The risk-free interest rate was based on the Treasury Constant Maturity Rates published by the U.S. Federal Reserve for periods applicable to the expected life of the warrants. The expected dividend yield was based on the Company’s current and expected dividend policy and the expected term is equal to the contractual life of the warrants.

Summary_of_Significant_Account

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Basis of Consolidation [Policy Text Block]	'
	Basis of Consolidation
	These financial statements include the accounts of Lightbridge, a Nevada corporation, and our wholly-owned subsidiaries, Thorium Power Inc., a Delaware corporation, Lightbridge International Holding LLC, a Delaware limited liability company and our foreign branch offices.
	All significant intercompany transactions and balances have been eliminated in consolidation. We registered a branch office in the United Kingdom in 2008 called Lightbridge Advisors Limited and we also established a branch office in Moscow, Russia, in July 2009, both of which are wholly owned by Lightbridge International Holding LLC. Translation gains and losses for the three months and nine months ended September 30, 2014 and September 30, 2013, were not significant.
Use of Estimates and Assumptions [Policy Text Block]	'
	Use of Estimates and Assumptions
	The preparation of financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Significant Estimates [Policy Text Block]	'
	Significant Estimates
	These accompanying consolidated financial statements include some amounts that are based on management’s best estimates and judgments. The most significant estimates relate to valuation of stock grants and stock options, the valuation allowance on deferred tax assets and various contingent liabilities. It is reasonably possible that these above-mentioned estimates and others may be adjusted as more current information becomes available, and any adjustment could be significant in future reporting periods. It is also reasonably possible that the actual grant date value of the stock options vested might have been materially different than the estimated value.
Certain Risks, Uncertainties and Concentrations [Policy Text Block]	'
	Certain Risks, Uncertainties and Concentrations
	We are an early stage company and will likely need additional funding by way of strategic alliances, further offerings of equity securities, an offering of debt securities, or a financing through a bank in order to support the remaining research and development activities required to further enhance and complete the development of our fuel products to a commercial stage. Currently, we are working on consulting revenue opportunities with the overall goal of increasing our profitability and cash flow.
	We participate in a government-regulated industry. Our operating results are affected by a wide variety of factors including decreases in the use or public favor of nuclear power, the ability of our technology to safeguard the production of nuclear power and our ability to safeguard our patents and intellectual property from competitors. Due to these factors, we may experience substantial period-to-period fluctuations in our future operating results. Potentially, a loss of a key officer, key management, and other personnel could impair our ability to successfully execute our business strategy, particularly when these individuals have acquired specialized knowledge and skills with respect to nuclear power and our operations.
	Our future operations and earnings currently depend on the results of the Company’s operations outside the United States. There can be no assurance that the Company will be able to successfully continue to conduct such operations, and a failure to do so would have a material adverse effect on the Company’s research and development activities, financial position, results of operations, and cash flows. Also, the success of the Company’s operations will be subject to other numerous contingencies, some of which are beyond management’s control. These contingencies include general and regional economic conditions, competition, changes in regulations, changes in accounting and taxation standards, inability to achieve overall long-term goals, future impairment charges and global or regional catastrophic events. Because the Company is dependent on its international operations for almost all its revenue, the Company may be subject to various additional political, economic, and other uncertainties.
	Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash equivalents and accounts receivable. Cash equivalents consist of a checking account held with one major financial institution with a high credit standing.
	Accounts receivable are typically unsecured and are primarily derived from revenues earned from customers located in the Middle East. We perform ongoing evaluations to determine customer credit and we limit the amount of credit we extend, but generally we do not require collateral from our customers. We maintain reserves for estimated credit losses; however, no reserve has been set up for 2014 and 2013, as we have not incurred any credit losses from our customers to date. Approximately 67% and 99% and 74% and 99% of our consulting revenues were from our Middle East contracts for the three months and nine months ended September 30, 2014 and 2013, respectively.
Revenue Recognition [Policy Text Block]	'
	Revenue Recognition
	Consulting Business Segment
	At present, we derive all of our revenue from our consulting and strategic advisory services business segment, by performing consulting services for governments outside the United States planning to create or expand electricity generation capabilities using nuclear power plants. Our fee structure for each client engagement is dependent on a number of variables, including the size of the client, the complexity of the project, the level of the opportunity for us to improve the client’s electrical generation capabilities using nuclear power plants, and other factors. The accounting policy we use to recognize revenue depends on the terms and conditions of the specific contract.
	Revenues from government-owned entities in the UAE are billed and recognized on a time and expense basis.
	Certain customer arrangements require evaluation of the criteria outlined in the accounting standards for reporting revenue “ Gross as a Principal Versus Net as an Agent ” in determining whether it is appropriate to record the gross amount of revenue and related costs, or the net amount earned as agent fees. Generally, when we are primarily obligated in a transaction, revenue is recorded on a gross basis. Other factors that we consider in determining whether to recognize revenue on a gross versus net basis include our assumption of credit risk, latitude in establishing prices, our determination of service specifications and our involvement in the provision of services. We have determined, based on the credit risk that we bear for collecting consulting fees, travel costs and other reimbursable costs from our customers, that in 2014 and 2013 we acted as a principal, and therefore we are recognizing as revenue all travel costs and other reimbursable costs billed to our customers.
	Cost of consulting services includes labor, travel expenses and other related consulting costs. All costs directly related to producing work under certain consulting agreements where revenue is recognized upon acceptance of certain contractual milestones by our customer, are first capitalized as deferred project costs. Deferred project costs are then recognized or amortized to an expense captioned “cost of consulting services provided” on the accompanying consolidated statement of operations, when the revenue is recognized upon the delivery and acceptance of the defined contractual milestones or deliverables.
	Technology Business Segment
	Once our nuclear fuel designs have advanced to a commercially usable stage by a fuel fabricator and/or nuclear plant owner/operator, we will seek to license our technology to them or to major government contractors working for the applicable government. We expect that our revenue from these license fees will be recognized on a straight-line basis over the expected period of the related license term.
Stock-Based Compensation [Policy Text Block]	'
	Stock-Based Compensation
	The stock-based compensation expense incurred by Lightbridge for employees and directors in connection with its stock option plan is based on the employee model of ASC 718, and the fair market value of the options is measured at the grant date. Under ASC 718 employee is defined as, “An individual over whom the grantor of a share-based compensation award exercises or has the right to exercise sufficient control to establish an employer-employee relationship based on common law as illustrated in case law and currently under U.S. Tax Regulations.” Our advisory board members and consultants do not meet the employer-employee relationship as defined by the IRS and therefore are accounted for under ASC 505-50.
	ASC 505-50-30-11 (previously EITF 96-18) further provides that an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date:
		i.	The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and
		ii.	The date at which the counterparty’s performance is complete.
	We have elected to use the Black-Scholes pricing model to determine the fair value of stock options on the measurement date of the grant. Restricted stock units are measured based on the fair market values of the underlying stock on the measurement date of the grant. Shares that are issued to officers on the exercise dates of their stock options may be issued net of the statutory withholding requirements to be paid by us on behalf of our employees. As a result, the actual number of shares issued will be fewer than the actual number of shares exercised under the stock option. We recognize stock-based compensation using the straight-line method.
	For the three months ended September 30, 2014 and 2013, we recognized stock-based compensation of approximately $0.1 million and $0.1 million. For the nine months ended September 30, 2014 and 2013, we recognized stock-based compensation of approximately $0.2 million and $0.3 million, respectively. Related income tax benefits were not recognized, as we incurred a tax loss for both years.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The carrying amounts of our financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate fair value because of their generally short maturities. We carry marketable securities at fair value.
Cash and Cash Equivalents, Restricted Cash and Marketable Securities [Policy Text Block]	'
	Cash and Cash Equivalents, Restricted Cash and Marketable Securities
	We invest our excess cash in money market mutual funds, and mutual bond funds. We classify all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months as marketable securities. We hold cash balances in excess of the federally insured limits of $250,000 with one prominent financial institution. We deem this credit risk not to be significant as our cash is held by a major prominent financial institution. Total cash and cash equivalents held in checking accounts and a money market core cash account, as reported on the accompanying consolidated balance sheets, totaled approximately $0.4 million and $3.7 million at September 30, 2014 and December 31, 2013, respectively.
	Restricted cash represents cash being held by the same prominent financial institution that is being used as collateral for our corporate credit cards and future letters of credit that we may issue to some of our foreign customers. The total balance of our restricted cash at September 30, 2014 and December 31, 2013, was approximately $0.6 million.
	We determine the appropriate classification of our investments in marketable securities at the time of purchase and reevaluate such designation at each balance sheet date. We have classified and accounted for our marketable securities as available-for-sale, however, we carry these securities at fair value (see below election made to value these financial instruments at fair market value). The fair value of substantially all securities is determined by quoted market prices.
	All marketable securities are classified as available-for-sale securities and are reported at their fair value (level 1). A level 1 measurement under the FASB pronouncements is the first tier of a three tier hierarchy for fair value measurements used in valuation methodologies. This valuation level allows for fair value measurements where the inputs are the quoted prices for the assets in the active markets. All of our marketable securities have quoted market prices and these quoted prices are used to determine the fair value of our marketable securities.
	The total quoted fair value of our marketable securities at September 30, 2014 and December 31, 2013, was approximately $16,000. This amount was held in Vanguard High Yield Corp Investor Fund (Symbol -VWEHX). The cost basis of this above investment was approximately $15,000.
	Investment Income (loss) is earned on marketable securities and consists of unrealized gains (losses), realized capital gains or losses, interest and dividends received, as reported to us from the financial institutions in which they were reinvested, and totaled approximately $0 and $2,000 for each of the three month periods ended September 30, 2014 and 2013, respectively, and $1,000 and $(9,000) for each of the nine months ended September 30, 2014 and 2013, respectively. We elected the fair value option permitted under FASB ASC 825 to report the unrealized gains and losses from our marketable securities in our accompanying consolidated statement of operations instead of other comprehensive income and loss. Management believes the fair value option provides a better indication of the Company’s performance.
Trade Accounts Receivable [Policy Text Block]	'
	Trade Accounts Receivable
	We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers which are past due, to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credits issued.
	There was no provision for doubtful accounts recorded at September 30, 2014 and December 31, 2013, as we have not experienced any bad debt write-offs from any of our customers. Substantially all accounts receivable at September 30, 2014 and December 31, 2013, are from the FANR and ENEC contracts (see Note 3-Accounts Receivable – Project Revenue and Reimbursable Project Costs).
Income Taxes [Policy Text Block]	'
	Income Taxes
	Income taxes are accounted for under the asset and liability method in accordance with United States generally accepted accounting principles. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized. We did not provide any current or deferred income tax provision or benefit for any periods presented to date because we have continued to experience a net operating loss since inception and therefore provide a 100% valuation allowance against all of our deferred tax assets (see Note 8–Income Taxes).
	The Company adopted the ASC standards relating to “ Accounting for Uncertainty in Income Taxes .” This pronouncement provides guidance for recognizing and measuring uncertain tax positions, as defined in the FASB accounting pronouncement “ Accounting for Income Taxes .” This pronouncement prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. This pronouncement also provides accounting guidance on derecognizing, classification and disclosure of these uncertain tax positions. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company has not recognized any interest and penalties in 2014 or 2013.
Foreign Currency [Policy Text Block]	'
	Foreign Currency
	The functional currency of our international branches is the local currency. We translate the financial statements of these branches to U.S. dollars using period-end rates of exchange for assets and liabilities, and average rates of exchange for revenues, costs, and expenses. The translation gains/losses for our branch office in Russia were not significant for the three and nine months ended September 30, 2014 and 2013.
Patents and Legal Costs [Policy Text Block]	'
	Patents and Legal Costs
	Patents are stated on the accompanying consolidated balance sheets at cost less accumulated amortization. The costs of the patents, once placed in service, will be amortized on a straight-line basis over their estimated useful lives or the remaining legal lives of the patents, whichever is shorter. The amortization periods for our patents can range between 17 and 20 years if placed into service at the beginning of their legal lives. Our patents have not been placed in service for the three months and nine months ended September 30, 2014 and 2013.
	Legal costs are expensed as incurred except for legal costs to file for patent protection, which are capitalized and reported as patents on the accompanying consolidated balance sheets.
Impairment of long-lived assets [Policy Text Block]	'
	Impairment of long-lived assets
	Long-lived assets of the Company are reviewed for impairment whenever events or circumstances indicate that the carrying amount of assets may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company did not consider it necessary to record any impairment charges for the three months and nine months ended September 30, 2014 and 2013.
Research, Development and Related Expenses [Policy Text Block]	'
	Research, Development and Related Expenses
	These costs from our Technology business segment are charged to operations in the period incurred and are shown on a separate line on the accompanying Consolidated Statements of Operations. Research and development and related expenses totaled approximately $0.1 million and $0.6 million for the three months ended September 30, 2014 and 2013, respectively. Research and development and related expenses totaled approximately $1.2 million and $1.8 million for the nine months ended September 30, 2014 and 2013, respectively.
Segment Reporting, Policy [Policy Text Block]	'
	Segment Reporting
	We use the “management approach” in determining reportable operating segments. The management approach considers the internal organization and reporting used by our chief decision makers for making operating decisions and assessing performance, as the source for determining our reportable segments. We have determined that we have two operating segments as defined by the FASB accounting pronouncement, “ Disclosures about Segments of an Enterprise and Related Information .” As discussed above, our two reporting business segments are our technology business and our consulting services business (See Note 9 - Business Segment Results).
Commitments and Contingencies [Policy Text Block]	'
	Commitments and Contingencies
	The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to account for and report contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment.
	If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.
	Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. The Company’s legal costs associated with contingent liabilities are recorded to expense as incurred.
Recent Accounting Pronouncements Recently Adopted [Policy Text Block]	'
	Recent Accounting Pronouncements
	In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016, (early adoption is not permitted). The guidance permits the use of either a retrospective or cumulative effect transition method.
	The Company does not expect the adoption of any recent accounting pronouncements to have a material impact on its financial statements.

Accounts_Payable_and_Accrued_L1

Accounts Payable and Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
			30-Sep-14		31-Dec-13
	Trade payables	$	0.1	$	0.1
	Accrued expenses and other		0.2		0.1
	Accrued payroll liabilities		0.1		0.3
	Total	$	0.4	$	0.5

Income_Taxes_Tables

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2014
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
			Total			Total			Deferred Tax Asset
			Sept. 30,			Dec. 31,			Sept. 30,			Dec. 31,
			2014			2013			2014			2013
	Capitalized start-up costs	$	4.2		$	4.6		$	1.7		$	1.8
	Stock-based compensation		17.8			17.6			7.1			7
	Net operating loss carry-forward		44.2			40.5			17.7			16.2
	Less: valuation allowance		(66.2	)		(62.7	)		(26.5	)		(25.0	)
		$	-		$	-		$	-		$	-

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended											12 Months Ended
	Sep. 30, 2014											Dec. 31, 2013
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'											'
					Weighted		Weighted									Weighted		Weighted
		Options			Average		Average						Options			Average		Average
		Outstanding			Exercise		Grant Date						Outstanding			Exercise		Grant Date
							Fair											Fair
					Price		Value									Price		Value
	Beginning of the year	1,564,257		$	11.16	$	10.42					Beginning of the year	1,639,842		$	11.46	$	10.85
	Granted	579,429			2.55		1.79					Granted	-			-		-
	Exercised	-			-		-					Exercised	-			-		-
	Forfeited	-		$	-	$	-					Forfeited	(7,250	)	$	6.04	$	5.51
	Expired	-		$	-	$	-					Expired	(68,335	)	$	18.94	$	16.9
	End of period	2,143,686		$	8.83	$	8.08					End of period	1,564,257		$	11.16	$	10.42
	Options exercisable	1,564,257		$	11.16	$	10.42					Options exercisable	1,530,200		$	11.28	$	10.73
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	'											'
		Stock Options Outstanding						Stock Options Vested					Stock Options Outstanding						Stock Options Vested
		Weighted						Weighted					Weighted						Weighted
		Average						Average					Average						Average
		Remaining					Weighted	Remaining			Weighted		Remaining					Weighted	Remaining			Weighted
		Contractual			Number		Average	Contractual	Number		Average		Contractual			Number		Average	Contractual	Number		Average
		Life			of		Exercise	Life	of		Exercise		Life			of		Exercise	Life	of		Exercise
		-Years			Awards		Price	-Years	Awards		Price		-Years			Awards		Price	-Years	Awards		Price
	Exercise											Exercise Prices
	Prices											$2.55 - $5.00	5.06			183,337	$	4.5	5.06	183,337	$	4.5
	$2.55 - $5.00	4.53			762,766	$	3.02	4.31	183,337	$	4.5	$5.01 - $12.90	5.11			782,584	$	7.45	5.03	748,527	$	7.53
	$5.01 - $12.90	4.36			782,584	$	7.45	4.36	782,584	$	7.45	$13.50 -	2.3			358,336	$	14.17	2.3	358,336	$	14.17
	$13.50 -	1.56			358,336	$	14.17	1.56	358,336	$	14.17	$19.20 -	2.12			240,000	$	23.85	2.12	240,000	$	23.85
	$19.20 -	1.37			240,000	$	23.85	1.37	240,000	$	23.85	Total	4			1,564,257	$	11.16	3.94	1,530,200	$	11.28
	Total	3.62			2,143,686	$	8.83	3.26	1,564,257	$	11.16
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	'											'
					Weighted
					Average
					Grant
		Number of			Date Fair
		Units			Value
	Total awards outstanding at December 31, 2012	43,032		$	6.49
	Units granted	-		$	-
	Units Exercised/Released	(28,739	)	$	6.99
	Units Cancelled/Forfeited	-		$	-
	Total awards outstanding at December 31, 2013	14,293		$	5.47
	Units granted	-		$	-
	Units Exercised/Released	(14,293	)	$	5.47
	Units Cancelled/Forfeited	-		$	-
	Total awards outstanding at September 30, 2014	-		$	-
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'											'
		Period
		ended
		9/30/14
	Average risk-free interest rate	1.68%
	Average expected life- years	5
	Expected volatility	90.44%
	Expected dividends	0

Business_Segment_Results_Table

Business Segment Results (Tables)	3 Months Ended																9 Months Ended
	Sep. 30, 2014																Sep. 30, 2014
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'																'
									Corporate and															Corporate and
		Consulting			Technology				Eliminations				Total					Consulting		Technology				Eliminations				Total
		2014	2013		2014		2013		2014		2013		2014		2013			2014	2013	2014		2013		2014		2013		2014		2013
	Revenue	275,158	169,156		-		-		-		-		275,158		169,156		Revenue	878,396	1,343,964	-		-		-		-		878,396		1,343,964
	Segment Profit – Pre Tax	201,954	(103,133	)	(116,145	)	(557,729	)	(847,121	)	(658,417	)	(761,312	)	(1,319,279	)	Segment Profit – Pre Tax	284,994	220,875	(1,172,680	)	(1,816,284	)	(2,962,657	)	(2,026,637	)	(3,850,342	)	(3,622,046	)
	Total Assets	138,026	628,789		801,447		672,405		1,313,364		1,383,090		2,252,837		2,684,284		Total Assets	138,026	628,789	801,447		672,405		1,313,364		1,383,090		2,252,837		2,684,284
	Property Additions	-	-		-		-		-		-		-		-		Property Additions	-	-	-		-		-		-		-		-
	Interest Expense	-	-		-		-		-		-		-		-		Interest Expense	-	-	-		-		-		-		-		-
	Depreciation	-	-		-		-		-		2,815		-		2,815		Depreciation	-	-	-		-		-		15,202		-		15,202

Basis_of_Presentation_Summary_1

Basis of Presentation, Summary of Significant Accounting Policies and Nature of Operations (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Value of nuclear science and technology center	'	'	$500,000,000	'	'	'
Extention of fuel cycle length	'	'	'24 months	'	'	'
Operating cycle length	'	'	'18 months	'	'	'
Maximum increase in power output	'	'	30.00%	'	'	'
Metallic fuel power uprate percentage	'	'	10.00%	'	'	'
Operating cycle length - Westinghouse-type	'	'	'24 months	'	'	'
Stock based compensation	'	'	227,274	273,558	'	'
Cash and Cash Equivalents, at Carrying Value	440,837	362,597	440,837	362,597	3,672,877	2,197,555
Valuation allowance	100.00%	'	100.00%	'	100.00%	'
Research and Development Expense	116,146	557,729	1,172,680	1,816,284	'	'
Minimum [Member]	'	'	'	'	'	'
Power output increase based on future potential reveunes	'	'	10.00%	'	'	'
Amortization period for patents	'	'	'17 years	'	'	'
Maximum [Member]	'	'	'	'	'	'
Power output increase based on future potential reveunes	'	'	17.00%	'	'	'
Federally insured cash limit	250,000	'	250,000	'	'	'
Amortization period for patents	'	'	'20 years	'	'	'
Approximations [Member]	'	'	'	'	'	'
Stock based compensation	100,000	100,000	200,000	300,000	'	'
Cash and Cash Equivalents, at Carrying Value	400,000	'	400,000	'	3,700,000	'
Restricted Cash	600,000	'	600,000	'	'	'
Marketable Securities	15,000	'	15,000	'	'	'
Unrealized gain loss from financial institutions	0	2,000	1,000	-9,000	'	'
Percentage of cost of consulting from one firm	67.00%	99.00%	74.00%	99.00%	'	'
Research and Development Expense	100,000	600,000	1,200,000	1,800,000	'	'
Vanguard High Yield Corp Investor Fund [Member] | Approximations [Member]	'	'	'	'	'	'
Marketable Securities	16,000	'	16,000	'	'	'
Cost basis of investments	$15,000	'	$15,000	'	'	'

Accounts_Receivable_Project_Re1

Accounts Receivable -Project Revenue and Reimbursable Project Costs (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Other Contract [Member]	'	'	'	'	'
Major customer revenue percentage	20.00%	'	20.00%	'	'
Approximations [Member]	'	'	'	'	'
Unbilled receivable	$100,000	'	$100,000	'	$100,000
Travel costs and reimbursable costs	100,000	100,000	100,000	100,000	'
Approximations [Member] | ENEC and FANR Projects [Member]	'	'	'	'	'
Accounts Receivable	$100,000	'	$100,000	'	$400,000
Major customer revenue percentage	74.00%	'	74.00%	'	100.00%
Approximations [Member] | FANR [Member]	'	'	'	'	'
Major customer revenue percentage	37.00%	'	37.00%	'	'

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	9 Months Ended	12 Months Ended	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2013
			Approximations [Member]	Approximations [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	40.00%	40.00%	'	'
Deferred Tax Assets, Operating Loss Carryforwards	'	'	$44,000,000	'
Valuation allowance	100.00%	100.00%	'	'
Change in valuation allowance	'	'	$1,500,000	$1,500,000

Commitments_and_Contingencies_

Commitments and Contingencies (Narrative) (Details) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended
	Oct. 16, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
Operating lease term	'1 year	'	'	'38 months
Approximations [Member]	'	'	'	'
Monthly rental fees	$32,000	'	'	$32,000
Rent expense	'	100,000	200,000	400,000
Approximations [Member] | Moscow Office [Member]	'	'	'	'
Monthly rental fees	'	'	'	$12,000

Research_and_Development_Costs1

Research and Development Costs (Narrative) (Details) (Approximations [Member], USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Approximations [Member]	'	'	'	'
Research and development costs	$100,000	$600,000	$1,200,000	$1,800,000
Consulting agreement monthly payments	'	'	$10,000	'

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Oct. 21, 2013

Jul. 22, 2010

Sep. 30, 2014

Oct. 21, 2013

Jul. 22, 2010

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Oct. 21, 2013

Jul. 22, 2010

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Oct. 21, 2013

Jul. 22, 2010

Sep. 30, 2014

Jul. 17, 2006

Sep. 30, 2014

Sep. 30, 2014

Jul. 17, 2006

Jul. 17, 2006

Jul. 17, 2006

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2012

Oct. 21, 2013

Approximations [Member]

Approximations [Member]

Approximations [Member]

Approximations [Member]

Chief Executive Officer [Member]

Issuance of 255,202 non-qualified 10 year options [Member]

Issuance of 1,667,181 non-qualified 8-10 year options [Member]

Registered Direct Offering and Outstanding Warrants [Member]

Registered Direct Offering and Outstanding Warrants [Member]

Registered Direct Offering and Outstanding Warrants [Member]

Registered Direct Offering and Outstanding Warrants [Member]

Registered Direct Offering and Outstanding Warrants [Member]

Issuance of 211,303 non-qualified 5-10 year options [Member]

May 5, 2014 Stock Options Granted [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum number of shares in respect to stock options [Member]

Employee Stock Option [Member]

Stock and Stock Equivalents [Member]

Stock Compensation Plan [Member]

Maximum restricted shares granted [Member]

Maximum restricted shares granted to one person [Member]

Stock-based compensation [Member]

Stock-based compensation [Member]

Stock-based compensation [Member]

Stock-based compensation [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Warrants [Member]

Approximations [Member]

Approximations [Member]

Chief Executive Officer [Member]

Directors, Officers and Employees [Member]

Issuance of 1,667,181 non-qualified 8-10 year options [Member]

Registered Direct Offering and Outstanding Warrants [Member]

Registered Direct Offering and Outstanding Warrants [Member]

Issuance of 211,303 non-qualified 5-10 year options [Member]

Chief Executive Officer [Member]

Directors, Officers and Employees [Member]

Issuance of 1,667,181 non-qualified 8-10 year options [Member]

Registered Direct Offering and Outstanding Warrants [Member]

Registered Direct Offering and Outstanding Warrants [Member]

Issuance of 211,303 non-qualified 5-10 year options [Member]

Approximations [Member]

Approximations [Member]

Approximations [Member]

Approximations [Member]

Common Stock, Shares Authorized

500,000,000

'

500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Outstanding

15,204,358

'

15,057,243

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19,500,218

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

2,152,174

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of options outstanding

2,143,686

'

1,564,257

1,639,842

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

43,032

'

Common Stock, Capital Shares Reserved for Future Issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

266,667

'

'

2,500,000

1,250,000

166,667

'

'

'

'

'

'

'

Number of options vested and expected to vest outstanding

1,564,257

'

1,530,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option expense

'

'

'

'

$102,000

$43,000

$207,000

$189,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-qualified stock options

'

'

'

'

'

'

'

'

820,396

255,202

1,677,181

'

'

'

'

'

211,303

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contractural lives

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'1 year 2 months 12 days

'1 year 9 months 18 days

'5 years

'

'

'5 years

'6 years 6 months

'6 years 6 months

'10 years

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Lower Limit

'

'

'

'

'

'

'

'

'

$4.50

$2.55

'

'

'

'

'

$2.55

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Upper Limit

'

'

'

'

'

'

'

'

'

$14.40

$23.85

'

'

'

'

'

$15.30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value

$2.30

'

$1.45

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation costs

0

'

19,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock grants estimated forfeiture amount

1.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

Share based compensation

227,274

273,558

'

'

100,000

100,000

200,000

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

100,000

200,000

300,000

'

'

'

Equity Issuance, Per Share Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued

15,204,358

'

15,057,243

'

'

'

'

'

'

'

'

'

'

132,822

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

305,490

0

'

'

'

'

'

'

'

'

'

'

'

305,000

4,400,000

13,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants sold

'

'

'

'

'

'

'

'

'

'

'

2,500,000

2,069,992

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock to be purchased in the Offering

'

'

'

'

'

'

'

'

'

'

'

1,250,000

1,034,996

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable term

'

'

'

'

'

'

'

'

'

'

'

'7 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock to be purchased by fixed combination

'

'

'

'

'

'

'

'

'

'

'

0.5

0.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price of fixed combination

'

'

'

'

'

'

'

'

'

'

'

1.75

6.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price

'

'

'

'

'

'

'

'

'

'

'

$2.30

$9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum common stock ownership to be eligible for exercise of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.99%

4.99%

'

'

'

'

9.99%

9.99%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from the Offering received after payments of fees and expenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount allocated from the Offering to common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount allocated from the Offering to warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Volitility rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

90.44%

'

'

'

'

'

'

'

'

'

'

'

'

'

90.44%

'

'

'

'

'

'

'

'

'

'

104.00%

Risk-free interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.68%

'

'

'

'

'

'

'

'

'

'

'

'

'

1.68%

'

'

'

'

'

'

'

'

'

'

2.01%

Dividend yield

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

0.00%

Expected term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'7 years 6 months

Strike Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.55

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options granted

579,429

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

579,429

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of stock options granted

'

'

$10.42

$10.85

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.79

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair market value on measurement date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.55

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-vesting forfeiture rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.50%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details) (Subsequent Event [Member], November 2014 Offering [Member], USD $)	1 Months Ended
	Nov. 17, 2014
Common stock and warrants sold	$2,878,516
Common stock to be purchased in the Offering	2,734,590
Shares of common stock to be purchased by fixed combination	0.95
Fixed combination, purchase price	1.75
Exercisable term	'7 years 6 months
Fixed combination exercise price	$2.31
Volitility rate	66.60%
Risk-free interest rate	2.07%
Dividend yield	0.00%
Expected term	'7 years 6 months
Approximations [Member]	'
Offering expenses	5,000,000
Proceeds from the Offering	4,400,000
Warrant [Member] | Approximations [Member]	'
Additional paid-in capital-stock and stock equivalents	1,700,000
Common Stock [Member] | Approximations [Member]	'
Additional paid-in capital-stock and stock equivalents	$2,700,000
Minimum [Member]	'
Maximum common stock ownership to be eligible for exercise of warrants	4.99%
Maximum [Member]	'
Maximum common stock ownership to be eligible for exercise of warrants	19.99%

Schedule_of_Accounts_Payable_a

Schedule of Accounts Payable and Accrued Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Total	$389,404	$476,628
Approximations [Member]	'	'
Trade payables	100,000	100,000
Accrued expenses and other	200,000	100,000
Accrued payroll liabilities	100,000	300,000
Total	$400,000	$500,000

Schedule_of_Deferred_Tax_Asset

Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Approximations [Member]	'	'
Capitalized start up costs	$4,200,000	$4,600,000
Share based compensation	17,800,000	17,600,000
Net operating loss carry-forward	44,200,000	40,500,000
Less: valuation allowance	-66,200,000	-62,700,000
Deferred Tax Assets, Net, Total	0	0
Deferred Tax Asset Amount [Member]	'	'
Capitalized start up costs	1,700,000	1,800,000
Share based compensation	7,100,000	7,000,000
Net operating loss carry-forward	17,700,000	16,200,000
Less: valuation allowance	-26,500,000	-25,000,000
Deferred Tax Assets, Net, Total	'	$0

Schedule_of_Sharebased_Compens

Schedule of Share-based Compensation, Stock Options, Activity (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Beginning of Period	1,564,257	1,639,842
Weighted Average Exercise Price Beginning of the Year	$11.16	$11.46
Weighted Average Fair Value Stock Options Beginning of the Year	$10.42	$10.85
Stock options granted	579,429	0
Weighted Average Exercise Price Stock Options Granted	$2.55	$0
Weighted Average Fair Value Stock Options Granted	$1.79	$0
Exercised	0	0
Weighted Average Exercise Price	$0	$0
Weighted Average Fair Value Stock Options Exercised	$0	$0
Forfeited	0	-7,250
Weighted Average Exercise Price Stock Options Forfeited	$0	$6.04
Weighted Average Fair Value Stock Options Forfeited	$0	$5.51
Expired	0	-68,335
Weighted Average Exercise Price Stock Options Expired	$0	$18.94
Weighted Average Fair Value Stock Options Expired	$0	$16.90
End of year	2,143,686	1,564,257
Weighted Average Exercise End of Year	$8.83	$11.16
Weighted Average Fair Value Stock Options End of Year	$8.08	$10.42
Options exercisable	1,564,257	1,530,200
Weighted Average Exercise Price Options exercisable	$11.16	$11.28
Weighted Average Fair Value Options exerciseable	$10.42	$10.73

Schedule_of_Disclosure_of_Shar

Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Weighted Average Remaining Contractural Life - Years	'3 years 7 months 13 days	'4 years	'
Number of options outstanding	2,143,686	1,564,257	1,639,842
Weighted Average Exercise Price Stock Options Outstanding	$8.83	$11.16	$11.46
Number of Awards Vested	1,564,257	1,530,200	'
Weighted Average Exercise Price	$11.16	$11.28	'
Weighted Average Remaining Contractual Life of Stock Options Vested	'3 years 3 months 4 days	'3 years 11 months 8 days	'
Range 1 [Member]	'	'	'
Exercise price lower range limit	$2.55	$2.55	'
Exercise price upper range limit	$5	$5	'
Weighted Average Remaining Contractural Life - Years	'4 years 6 months 11 days	'5 years 22 days	'
Number of options outstanding	762,766	183,337	'
Weighted Average Exercise Price Stock Options Outstanding	$3.02	$4.50	'
Number of Awards Vested	183,337	183,337	'
Weighted Average Exercise Price	$4.50	$4.50	'
Weighted Average Remaining Contractual Life of Stock Options Vested	'4 years 3 months 22 days	'5 years 22 days	'
Range 2 [Member]	'	'	'
Exercise price lower range limit	$5.01	$5.01	'
Exercise price upper range limit	$12.90	$12.90	'
Weighted Average Remaining Contractural Life - Years	'4 years 4 months 10 days	'5 years 1 month 10 days	'
Number of options outstanding	782,584	782,584	'
Weighted Average Exercise Price Stock Options Outstanding	$7.45	$7.45	'
Number of Awards Vested	782,584	748,527	'
Weighted Average Exercise Price	$7.45	$7.53	'
Weighted Average Remaining Contractual Life of Stock Options Vested	'4 years 4 months 10 days	'5 years 11 days	'
Range 3 [Member]	'	'	'
Exercise price lower range limit	$13.50	$13.50	'
Weighted Average Remaining Contractural Life - Years	'1 year 6 months 22 days	'2 years 3 months 18 days	'
Number of options outstanding	358,336	358,336	'
Weighted Average Exercise Price Stock Options Outstanding	$14.17	$14.17	'
Number of Awards Vested	358,336	358,336	'
Weighted Average Exercise Price	$14.17	$14.17	'
Weighted Average Remaining Contractual Life of Stock Options Vested	'1 year 6 months 22 days	'2 years 3 months 18 days	'
Range 4 [Member]	'	'	'
Exercise price lower range limit	$19.20	$19.20	'
Weighted Average Remaining Contractural Life - Years	'1 year 4 months 13 days	'2 years 1 month 13 days	'
Number of options outstanding	240,000	240,000	'
Weighted Average Exercise Price Stock Options Outstanding	$23.85	$23.85	'
Number of Awards Vested	240,000	240,000	'
Weighted Average Exercise Price	$23.85	$23.85	'
Weighted Average Remaining Contractual Life of Stock Options Vested	'1 year 4 months 13 days	'2 years 1 month 13 days	'

Schedule_of_Sharebased_Compens1

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) (Restricted Stock [Member], USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Restricted Stock [Member]	'	'
Total awards outstanding beginning of the period	'	43,032
Weighted average grant date fair value total awards outstanding beginning of the period	'	$6.49
Units granted	0	0
Weighted average grant date fair value units Granted	$0	$0
Units Exercised/Released	-14,293	-28,739
Weighted average grant date fair value units exercised/released	$5.47	$6.99
Units Cancelled/Forfeited	0	0
Weighted average grant date fair value units Cancelled/Forfeited	'	$0
Total awards outstanding at June 30, 2014	0	14,293
Weighted Average Grant Date Fair value, Total awards outstanding at June 30, 2014	$0	$5.47

Schedule_of_Sharebased_Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) (Employee Stock Option [Member])	9 Months Ended
	Sep. 30, 2014
Employee Stock Option [Member]	'
Average risk-free interest rate	1.68%
Average expected life- years	'5 years
Expected volatility	90.44%
Expected dividends	0.00%

Schedule_of_Segment_Reporting_

Schedule of Segment Reporting Information, by Segment (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Revenue	$275,158	$169,156	$878,396	$1,343,964	'
Segment Profit - Pre Tax	-761,312	-1,319,279	-3,850,342	-3,622,046	'
Total Assets	2,252,837	2,684,284	2,252,837	2,684,284	5,657,639
Property Additions	0	0	0	0	'
Interest Expense	0	0	0	0	'
Depreciation	0	2,815	0	15,202	'
Consulting [Member]	'	'	'	'	'
Revenue	275,158	169,156	878,396	1,343,964	'
Segment Profit - Pre Tax	201,954	-103,133	284,994	220,875	'
Total Assets	138,026	628,789	138,026	628,789	'
Property Additions	0	0	0	0	'
Interest Expense	0	0	0	0	'
Depreciation	0	0	0	0	'
Technology [Member]	'	'	'	'	'
Revenue	0	0	0	0	'
Segment Profit - Pre Tax	-116,145	-557,729	-1,172,680	-1,816,284	'
Total Assets	801,447	672,405	801,447	672,405	'
Property Additions	0	0	0	0	'
Interest Expense	0	0	0	0	'
Depreciation	0	0	0	0	'
Corporate and Eliminations [Member]	'	'	'	'	'
Revenue	0	0	0	0	'
Segment Profit - Pre Tax	-847,121	-658,417	-2,962,657	-2,026,637	'
Total Assets	1,313,364	1,383,090	1,313,364	1,383,090	'
Property Additions	0	0	0	0	'
Interest Expense	0	0	0	0	'
Depreciation	$0	$2,815	$0	$15,202	'